Pancreatic cancer

Current Problems in Surgery

Volumn 36, Issue 2, 1999, Pages 66-152

  Yeo, Charles J ^a   Cameron, John L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; CANCER STAGING; GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASM; PALLIATIVE THERAPY; PANCREAS; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; PROGNOSIS; REVIEW;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; PALLIATIVE CARE; PANCREAS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS;

EID: 0033071558     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-3840(99)80805-3     Document Type: Article

References (155)

1. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin North Am 1998;7:67-91.
2. Lowenfels AB, Maissoneuve P, Boyle P. Epidemiology of pancreatic cancer. In: Howard JM, Idezuki Y, Ihse I, Prinz RA, editors. Surgical diseases of the pancreas. 3rd ed. Baltimore (MD): Williams and Wilkens; 1998. p. 433-7.
3. Miller BA, Silverman DT, Kaplan R. Pancreas, In: Miller BA, Ries LAG, Hankey BF, et al, editors. SEER cancer statistics review: 1973-1990. Bethesda (MD): National Cancer Institute, NIH; 1993. p. XX1.1-.15.
4. Parkin DM, Muir CS, Whelan SL, et al, editors. Cancer incidence in five continents. Lyon (France): International Agency for Research on Cancer; 1992. p. 11033.
5. Chow H-W, Gridley G, Nyren O, et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995;87:930-1.
6. La Vecchia C, Negri E, D'Avanzo B, et al. Medical history, diet and pancreatic cancer. Oncology 1990;47:463-6.
7. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 1995;273:1605-9.
8. Whittemore AS, Paffenbarger RS Jr, Anderson K, et al. Early precursors of pancreatic cancer in college men. J Chronic Dis 1983;36:251-6.
9. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pan-creatic cancer: International Pancreatitis Study Group. N Engl J Med 1993;328: 1433-7.
10. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995; 109:247-51.
11. Fernandez E, LaVecchia C, Porta M, et al. Pancreatitis and the risk of pancreatic cancer. Pancreas 1995;11:185-9.
12. Karlson BM, Ekbom A, Josefsson S, et al. The risk of pancreatic cancer following pancreatitis: an assocation due to confounding? Gastroenterology 1997;! 13:587-92.
13. Neglia JP, Fitzsimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. N Engl J Med 1995;332:494-9.
14. Ji B-T, Hatch MC, Chow W-H, et al. Anthropométrie and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. Int J Cancer 1996:66:432-7.
15. Mills PK, Beeson WL, Abbey DE, et al. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988;61:2578-85.
16. Gold EB. Epidemiology of and risk factors for pancreatic cancer. Surg Clin North Am 1995;75:819-43.
17. Howe GR, Burch JD. Nutrition and pancreatic cancer. Cancer Causes Control 1996:7:69-82.
18. MacMahon B, Yen S, Trichopoulos D, et al. Coffee and cancer of the pancreas. N Engl J Med 1981;304:630-3.
19. Hsieh C-C, MacMahon B, Yen S, et al. Coffee and pancreatic cancer (chapter 2). N Engl J Med 1986;315:587-9.
20. Angevine DM, Jablon S. Late radiation effects of neoplasia and other diseases in Japan. Ann N Y Acad Sei 1964;! 14:823-31.
21. Thompson DE, Mabuchi K, Ron E, et al. Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958-1987. Radiât Res 1994; 137:817-67.
22. Wilentz RE, Hruban RH. Pathology of cancer of the pancreas. Surg Oncol Clin N Am 1998;7:43-65.
23. DiGiuseppe JA, Yeo CJ, Hruban RH. Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas. Adv Anat Pathol 1996;3:139-55.
24. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976;36:2690-8.
25. Furukawa T, Chiba R, Kobari M, et al. Varying grades of epithelial atypia in the pancreatic ducts of humans. Arch Pathol Lab Med 1994; 118:227-34.
26. Brat DJ, Lillemoe KD, Yeo CJ, et al. Progression of pancreatic intraductal neoplasms to infiltrating adenocarcinoma of the pancreas. Am J Surg Path 1998;22:163-9.
27. Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinoma of the pancreas: a clinicopathologic study of 28 cases. Am J Surg Pathol 1992;16:815-37.
28. Z'graggen K, Rivera JA, Compton CC, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 1997;226:491-500.
29. Griffin CA, Hruban RH, Long PP, et al. Chromosome abnormalities in pancreatic adenocarcinoma. Genes Chromosomes Cancer 1994;9:93-100.
30. Griffin CA, Hruban RH, Morsberger LA, et al. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res 1995;55:2394-9.
31. Hruban RH, Petersen GM, Ha PK, Kern SE. Genetics of pancreatic cancer: from genes to families. Surg Oncol Clin N Am 1998;7:1-23.
32. Seymour AB, Hruban RH, Redston M, et al. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994;54:2761-4.
33. Hahn SA, Seymour AB, Hoque ATMS, et al. Allelotype of pancreatic cancer using xenograft enrichment. Cancer Res 1995;55:4670-5
34. Brat DJ, Hahn SA, Griffin CA, et al. The structural basis of molecular genetic deletions: an integration of classical cytogenetic and molecular analysis of pancreatic adenocarcinoma. Am J Pathol 1997; 150:383-91.
35. Hahn SA, Schutte M, Shamsul Hoque ATM, et al. DPC4, a candidate tumor-suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
36. Schutte M, da Costa LT, Hahn SA, et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sei USA 1995;92:5950-4.
37. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996:56:5360-4.
38. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
39. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal mucinous cell hyperplasia. Cancer Res 1994;54:3568-73.
40. Goggins M, Offerhaus GJA, Hilgers W, et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with a characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998; 152:1501-7.
41. Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1997;57:4420-6.
42. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996;14:141-5.
43. Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterol 1997;113:1063-8.
44. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
45. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreas cancer: a review. Semin Oncol 1996;23:251-75.
46. Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996; 13:120-2.
47. Goldstein AM, Fräser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p!6 mutations. N Engl J Med 1995;333:970-4.
48. Moskaluk CA, Hruban RH, Lietman A, et al. Novel germline p!6 (INK4a) mutation in familial pancreatic carcinoma. Hum Mutat(In press).
49. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to Pl-3 kinase. Science 1995:268:1749-53.
50. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the PeutzJeghers syndrome. N Engl J Med 1987;316:1511-4.
51. Fernandez E, La Vecchia C, D'Avanzo B, et al. Family history and the risk of liver, gallbladder and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 1994;3: 209-12.
52. Ghadirian P, Boyle P, Simard A, et al. Reported family aggregation of pancreatic cancer within a population-based case-control study in the francophone: community in Montreal, Canada. Int J Pancreatol 1991; 10:183-96.
53. Lumadue JA, Griffin CA, Osman M. et al. Familial pancreatic cancer and the genetics of pancreatic cancer. Surg Clin North Am 1995;75:845-55.
54. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Gin N Am 1998;7:25-41.
55. Lemoine NR, Hughes CM, Barton CM, et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992; 166:7-12.
56. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor-beta isoforms in human pancreatic cancer correlates with decreased survival. Gastroenterol 1993:105:1846-56.
57. Mason IJ. The ins and outs of fibroblast growth factors. Cell 1994;78:547-52.
58. Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer 1994:59:667-75.
59. Bergmann U, Funatomi H, Yokoyama M, et al. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995:55:2007-11.
60. Union Internationale Contra Le Cancer (UICC). TNM classification of malignant tumors. 4th ed. New York: Springer Verlag; 1987.
61. Japan Pancreas Society. General rules for surgical and pathological studies on cancer of the pancreas. 3rd ed. Tokyo: Kanehara and Co; 1987.
62. Cujik J, Babiker AG. Pancreatic cancer, diabetes mellitus and gallbladder disease. Int J Cancer 1989;43:415-21.
63. Ritts RE, Pitt HA. CA19-9 in pancreatic cancer. Surg Oncol Clin N Am 1998;7:93-101.
64. Ritts R, Nagorney D, Jacobsen D, et al. Comparison of preoperative CA19-9 levels with results of other diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic cancer or gallbladder disease. Pancreas 1994;9:707-16.
65. Willett C. Daly W, Warshaw A. CA19-9 is an index of response to rieoadjuvant chemoradiation in pancreatic cancer. Am J Surg 1996; 172:350-2.
66. Bluemke DA, Abrams RA, Yeo CJ, et al. Recurrent pancreatic adenocarcinoma: spiral CT evaluation following the Whipple procedure. RadioGraphics 1997;17: 303-13.
67. Berthelemy P, Bouisson M, Escourrou J, et al. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Int Med 1995:123: 188-91.
68. Wilentz RE, Chung CH, Sturm PDJ, et al. K-ras mutations in duodenal fluid of patients with pancreas carcinoma. Cancer 1998;82:96-103.
69. Bluemke DA, Fishman EK. CT and MR evaluation of pancreatic cincer. Surg Oncol Clin N Am 1998:7:103-24.
70. Trede M, Rumstadt B, Wendl K, et al. Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors. Ann Surg 1997;226:393-407.
71. Inokuma T, Tamaki N, Torizuka T, et al. Value of fluorine- 18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 1995;36:229-35.
72. Savader BL, Fishman EK, Savader S, Cameron JL. CT arterial portography versus pancreatic angiography in the assessment of vascular involvement in pancreatic and periampullary tumors. J Comput Assist Tomogr 1994;18:916-20.
73. Furukawa H, Kosuge T, Mukai K, et al. Helical computed tomography in the diag-nosis of portal vein invasion by pancreatic head carcinoma. Arch Surg 1998; 133:61-5.
74. Dooley WC, Cameron JL, Pitt HA, et al. Is preoperative angiography useful in patients with periampullary tumors? Ann Surg 1990;211:649-55.
75. Bakkevold KE, Arnesjo B, Kambestad B. Carcinoma of the pancreas and papilla of Vater: assessment of resectability and factors influencing resectability in stage 1 carcinomas: a prospective multicenter trial of 472 patients. Eur J Surg Oncol 1992; 18:494-507.
76. Rösch T, Lorenz R, Braig C, et al. Endoscopie ultrasound in pancreatic tumor diagnosis. Gastrointest Endosc 1991;37:347-52.
77. Snady H, Cooperman A, Siegel J. Endoscopie ultrasound compared with computed tomography with ERCP in patients with obstructive jaundice or small peripancreatic mass. Gastrointest Endosc 1992;38:27-34.
78. Muller MF, Meyenberger C, Bertschinger P, et al. Pancreatic tumors: evaluation with endoscopie US, CT and MR imaging. Radiology 1994; 190:745-57.
79. Stevens PD, Lightdale CJ. The role of endosonography in the diagnosis and management of pancreatic cancer. Surg Oncol Clin N Am 1998;7:125-33.
80. Wiersema MJ, Vilman P, Giovannini M, et al. Endosonography-guided fine-needle aspiration biopsy: diagnosticaccuracy and complication assessment. Gastroenterology 1997;112:1087-9.
81. Bemelman WA, de Wit LTh, van Delden OM, et al. Diagnostic laparoscopy combined with laparoscopic ultrasonography in staging of cancer of the pancreatic head region. Br J Surg 1995;82:820-4.
82. Gallery MP, Strasberg SM, Doherty GM, et al. Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy. J Am Coll Surg 1997;185:33-9.
83. Andren-Sandberg A, Lindberg CG, Lundstedt C, et al. Computed tomography and laparoscopy in the assessment of the patient with pancreatic cancer. J Am Coll Surg 1998; 186:35-40.
84. Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996;223:134-40.
85. John TG, Greig JD, Carter DC, et al. Carcinoma of the pancreatic head and periampullary region: tumor staging with laparoscopy and laparoscopic ultrasonography. Ann Surg 1995;221:156-64.
86. Fernandez-del Castillo C, Warshaw AL. Laparoscopic staging and peritoneal cytology. Surg Oncol Clin N Am 1998;7:135-42.
87. Fernandez-del Castillo C, Warshaw AL. Peritoneal métastases in pancreatic carcinoma. Hepatogastroenterology 1993;40:430-2.
88. Fernandez-del Castillo C, Rattner DW, Warshaw AL. Further experience with laparoscopy and peritoneal cytology in staging for pancreatic cancer. Br J Surg 1995;82:1127-9.
89. Warshaw AL, Gu Z-Y, Wittenberg J, et al. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990;125:230-3.
90. Sohn TA, Yeo CJ, Cameron JL, et al. Should pancreaticoduodenectomy be performed in octogenarians? J Gastrointest Surg 1998;2:207-16.
91. Soehendra N, Reynders-Frederix V. Palliative bile duct drainage: a new endoscopie method of introducing a transpapillary drain. Endoscopy 1980; 12:8-10.
92. Lichtenstein DR, Carr-Locke DL. Endoscopie palliation for unresectable pancreatic cancer. Surg Clin North Am 1995;75:969-88.
93. Molnar W, Stockum AE. Relief of obstructive jaundice through percuUineous transhepatic catheter: a new therapeutic method. AJR Am J Roentgenol 1974;122:356-67.
94. Kaufman SL. Percutaneous palliation of unresectable pancreatic cancer. Surg Clin North Am 1995;75:989-99.
95. Speer AG, Cotton PB, Russell RCG, et al. Randomized trial of endoscopie versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987;2:57-62.
96. Watanapa P, Williamson RCN. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg 1992;79:8-20.
97. Lillemoe KD. Palliative therapy for pancreatic cancer. Surg Oncol Clin N Am 1998:7:199-216.
98. Levy MH. Pharmacology treatment of cancer pain. N Engl J Med 1996;335:1124-32.
99. Sarr MG, Cameron JL. Surgical management of unresectable carcinoma of the pancreas. Surgery 1983;91:123-33.
100. Singh SM, Reber HA. Surgical palliation for pancreatic cancer. Surg Clin North Am 1989;69:599-611.
101. Lillemoe KD, Sauter PK, Pitt HA, et al. Current status of surgical palliation of periampullary carcinoma. Surg Gynecol Obstet 1993;176:1-10.
102. Copping J, Willix R, Kraft R. Palliative chemical splanchnicectomy. Arch Surg 1978;113:509-11.
103. Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer: a prospective randomized trial. Ann Surg 1993:217:447-57.
104. Kausch W. Das Carcinom der Papilla Duodeni und seine radikale Entfeinung. Beitrage zur Klinische Chirurgie 1912;78:439-86.
105. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 1935;102:763-79.
106. Traverse LW, Longmire WP. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146:959-62.
107. LaValle GJ, Martinez DA, Sobel D, et al. Assessment of disseminated pancreatic cancer: a comparison of traditional exploratory laparotomy and radioimmunoguided surgery. Surgery 1997;122:867-73.
108. Cameron JL. Rapid exposure of the portal and superior mesenterie veins. Surg Gynecol Obstet 1993; 176:395-8.
109. Pikarsky AJ, Muggia-Sullam M, Eid A, et al. Pancreaticogastrostomy after pancreaticoduodenectomy: a retrospective study of 28 patients. Arch Surg 1997;132:296-9.
110. Yamamoto J, Shimamura Y, Nakahara H, et al. Simple technique for pancreatogastrostomy and the histological findings of pancreatogastric anastomosis. Arch Surg 1997:132:785-8.
111. Yeo CJ, Cameron JL, Mäher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995;222:580-92.
112. Cameron JL, Pitt HA, Yeo CJ, et al. One hundred and forty five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993;217:430-8.
113. Trede M, Schwall G, Saeger H-D. Survival after pancreaticoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447-58.
114. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995:221:721-33.
115. Yeo CJ, Abrams RA, Grochow LB. et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single institution experience. Ann Surg 1997;225:62136.
116. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, outcomes. Ann Surg 1997; 226:248-60.
117. Yeo CJ. Management of complications following pancreaticoduodenectomy. Surg Clin North Am 1995:75:913-24.
118. Yeo CJ, Barry MK, Sauter PK, et al. Erythromycin accelerates gastric emptying following pancreaticoduodenectomy: a prospective, randomized placebo controlled trial. Ann Surg 1993:218:229-38.
119. Yeo CJ. Pylorus-preserving pancreaticoduodenectomy. Surg Oncol Clin N Am 1998;7:143-56.
120. Allison DC, Bose KK, Hruban RH, et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreaticoduodenectomy. Ann Surg 1991:214:648-56.
121. Gordon TA. Burleyson GP, Tielsch JM, Cameron JL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995:221:43-9.
122. Sosa JA, Bowman HM, Bass EB, et al. Importance of hospital volume in the surgical management of pancreatic cancer. Surg Forum 1997:48:584-6.
123. Lieberman MD, Kilburn H. Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995:222:638-45.
124. Kaiser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985:120:899-903.
125. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987:59:2006-10.
126. Bosset J. Pay JJ, Giblet M, et al. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study. Radiother Oncol 1992:24:191-4.
127. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combined chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater: results of a controlled, prospective, randomized multicenter trial. Eur J Cancer 1993;29A:698-703.
128. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993:165:68-73.
129. Yeo CJ, Cameron JL. Pancreatic cancer: current controversies. In: Schein M, Wise L, editors. Clinical controversies in surgery. Basel (Switzerland): Karger Landes; 1998. p. 70-7.
130. Nordback IH, Hruban RH, Buitnott JK, et al. Carcinoma of the body and tail of the pancreas. Am J Surg 1992:164:26-31.
131. Dalton RR, Sarr MG, van Heerden JA, Colby TV. Carcinoma of the body and tail of the pancreas: Is curative resection justified? Surgery 1992;111:489-94.
132. Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996:223:506-12.
133. Sperti C, Pasquali C, Pedrazzoli S. Ductal adenocarcinoma of the body and tail of the pancreas. J Am Coll Surg 1997;185:255-9.
134. Wade TP, Virgo KS, Johnson FE. Distal pancreatectomy for cancer: results in US Department of Veterans Affairs Hospitals, 1987-1991. Pancreas 1995:11:341-4.
135. Abrams RA, Grochow LB. Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head. Surg Clir North Am 1995:75:925-38.
136. Dobelbower RR, Battle JA. Radiotherapy, In: Howard JM, Idezuki Y, Ihse I, Prinz RA, editors. Surgical diseases of the pancreas. 3rd ed. Baltimore (MD): Williams andWilkens; 1998. p. 587-95.
137. Moertel CG. Childs DS Jr, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-7.
138. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectabls pancreatic carcinoma: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluorouracil), and high dose radiation + 5fluorouracil. Cancer 1981:48:1705-10.
139. Coia L, Hoffman J, Scher R, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiât Oncol Biol Phys 1994:30:161-7.
140. Miller AR, Robinson EK, Lee JE, et al. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Surg Oncol Clin North Am 1998;7:183-97.
141. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127: 1335-9.
142. Spitz PR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperativ; chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997:15:928-37.
143. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8.
144. Casper ES, Green MR, Kelsen DP, et al. Phase II trial ofgemcitabine (2', 2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994:12:29-34.
145. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2'.2'-difluoro-2'-deoxycytidine. Int J Radiol Oncol Bio Physics 1996:34:867-72.
146. Andren-Sandberg A, Backman PL. Hormonal therapy and immunotherapy. In: Howard JM, Idezuki Y, Ihse I, Prinz RA, editors. Surgical diseases of the pancreas. 3rd ed. Baltimore (MD): Williams andWilkens; 1998. p. 613-22.
147. Wong A, Chan A, Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 1987:71:749-50.
148. Bakkevold KE, Pettersen A, Arnesjo B, et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and papilla of Vater. Br J Surg 1990:77:725-30.
149. Abbruzzese JL, Gholson CF, Daugherty K, et al. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 1992:7:165-71.
150. Clary BM, Lyerly HK. Gene therapy and pancreatic cancer. Surg Oncol Clin N Am 1998;7:217-37.
151. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sei Am 1998;4:194-203.
152. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunology Today 1993; 14:483-6.
153. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 1995;13:399-415.
154. Dranoff G, Jaffee EM, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte/macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sei USA 1993;90:3539-43.
155. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class-I restricted tumor antigens. Science 1994;264:961-5.